Revenue Recognition (Details) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Apr. 30, 2016	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) item	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Agreement term	4 years
Deferred revenue		$ 37,309			$ 37,309		$ 1,420
Total revenues		63,069		$ 52,283	125,409	$ 101,665
Noncurrent deferred revenue		36,135			36,135
Deferred revenue, current portion		1,174			1,174		$ 1,420
Product
Revenue recognized		900			1,800
Total revenues		60,353		50,929	$ 114,622	99,323
Product | Minimum
Performance obligation, expected timing					9 months
Product | Maximum
Performance obligation, expected timing					12 months
Licensing and other
Total revenues		2,716		$ 1,354	$ 10,787	$ 2,342
Genetic testing services and provision of IVD kits
Revenue recognized		600			500
Evercord
Noncurrent deferred revenue		1,700			$ 1,700
Evercord | Processing and storage services
Number of performance obligations | item					2
Evercord | Processing and storage services | Minimum
Performance obligation, expected timing					6 months
Evercord | Processing and storage services | Maximum
Performance obligation, expected timing					18 months
Evercord | Processing and storage services | Alternate
Performance obligation, expected timing					12 months
Qiagen
Revenue recognized		100	$ 5,500		$ 5,600
Revenue, remaining performance obligation		9,400			9,400
Noncurrent deferred revenue		$ 34,400			$ 34,400
Qiagen | The Qiagen Agreement
Agreement term					10 years
Initial transaction price			$ 15,000
Laboratory distribution partners | Product | Minimum
Performance obligation, expected timing					2 months
Laboratory distribution partners | Product | Maximum
Performance obligation, expected timing					3 months